Latest Regulatory Progress News

Syntara Limited has raised A$10 million through a two-tranche placement and share purchase plan, backing its Phase 2b myelofibrosis trial and multiple clinical readouts following positive FDA feedback.

Prodigy Gold has boosted the indicated resource at its Hyperion Gold Deposit by 70%, lifting total resources to 454,000 ounces and progressing key mining approvals and joint ventures.

TrivarX appoints Dr Danielle Meyrick as CEO to spearhead clinical trials and commercialisation of its novel stable isotope MRI brain cancer imaging platform, with Phase 1 studies on track for completion this year.

New Frontier Minerals has secured technical approval for its Big One Copper Deposit Mining Lease Application, updated exploration targets across multiple copper prospects, and expanded its rare earths footprint in Australia and Canada.

Lake Resources made solid progress on the Exploitation Environmental Impact Assessment for its Kachi Lithium Brine Project, targeting approval in Q3 2026, while maintaining strong liquidity and strategic partnerships.

NH3 Clean Energy has marked strong progress in its WAH2 clean ammonia project by appointing Linde Engineering for FEED and securing a 15-year water supply agreement, setting the stage for a final investment decision by year-end.

Imricor Medical Systems advanced FDA clearances and expanded clinical trials in Q1 CY26, positioning for commercial growth despite higher operating cash outflows.

TMK Energy’s Gurvantes XXXV project hit a new daily gas production record exceeding 1,350 m³, confirming commercial desorption. The company secured $6 million in funding and regulatory approval to drill three new pilot wells and advance domestic gas use in Mongolia.

Jade Gas Holdings has secured Mongolian regulator approval for its TTCBM Project appraisal report, paving the way for reserve booking and submission of a development plan toward Mongolia's first significant gas operation.

Santana Minerals advanced its Bendigo-Ophir Gold Project in New Zealand with a confirmed consent decision date, major equipment agreements, and a substantial capital raise, setting the stage for development.

Bio-Gene Technology is progressing critical toxicology studies for Flavocide with a targeted APVMA submission in March 2027, while forging a strategic partnership to launch Qcide insecticides in Japan by late 2026.

Island Pharmaceuticals has cleared a major regulatory hurdle with the US FDA, confirming a clinical development path for its antiviral Galidesivir under the Animal Rule. Backed by a $9 million capital raise and strategic partnerships, the company is poised for potential US government procurement and biodefence market entry.